Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antipsychotics in bipolar disorders].

M-N Vacheron-Trystram1, A Braitman, S Cheref

  • 1Service du Docteur Caroli, Hôpital Sainte-Anne, 1 rue Cabanis, 75014 Paris, France.

L'Encephale
|January 1, 2005
PubMed
Summary

This review examines treatments for bipolar disorder, focusing on novel antipsychotic agents as alternatives to lithium. Atypical antipsychotics show promise for managing manic and depressive episodes with fewer side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The link between aggressive behavior and depression in adolescence. A cross-sectional study conducted in the psychiatric emergency unit at the Sainte-Anne hospital].

L'Encephale·2014
Same author

[Decision of emergency involuntary hospitalization: categorical or dimensional approach?].

L'Encephale·2013
Same author

[Clinical and socio-demographic profile of patients with schizophrenia according to the antipsychotic treatment prescribed].

L'Encephale·2006
Same author

[The practice of restraint in a psychiatric emergency unit].

L'Encephale·2004
Same author

[A case report of mania precipitated by use of DHEA].

L'Encephale·2002
Same author

[Chloral hydrate: a hypnotic best forgotten?].

L'Encephale·2002

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience
  • Mental Health Treatment

Background:

  • Bipolar disorder affects approximately 1% of the population, characterized by alternating depressive and manic episodes, often starting in younger individuals.
  • Subtypes include Bipolar I (manic episodes) and Bipolar II (depressive episodes), with cyclothymic disorder presenting milder, chronic fluctuations.
  • Lithium therapy is a traditional treatment but has limitations, including worsening depressive symptoms and poor response in certain patient groups like rapid cyclers or those with substance abuse.

Purpose of the Study:

  • To review current treatments for bipolar disorder, with a focus on novel antipsychotic agents in France.
  • To evaluate atypical antipsychotics as alternatives or adjuncts to lithium therapy and conventional antipsychotics.
  • To compare the efficacy and side effect profiles of various treatment strategies for bipolar disorder.

Related Experiment Videos

Main Methods:

  • Review of existing literature on bipolar disorder treatments, including clinical trials and observational studies.
  • Analysis of data on lithium therapy, conventional antipsychotics, and atypical antipsychotics (clozapine, risperidone, olanzapine).
  • Examination of treatment outcomes, efficacy in different bipolar subtypes, and adverse event profiles.

Main Results:

  • Atypical antipsychotics like olanzapine and risperidone demonstrate efficacy in treating acute mania and depressive symptoms, both as monotherapy and in combination with mood stabilizers.
  • While clozapine shows potential, its significant side effects (agranulocytosis, weight gain) limit its first-line use.
  • Olanzapine and risperidone appear to have favorable side effect profiles compared to conventional antipsychotics, with olanzapine showing comparable efficacy to lithium in some trials.
  • Combination therapy, particularly with atypical antipsychotics, is increasingly recognized as essential for managing the cyclic nature of bipolar and schizoaffective disorders.

Conclusions:

  • Atypical antipsychotics are emerging as valuable first-line agents for the adjunctive treatment of mania and psychotic depression due to their efficacy and improved side effect profiles.
  • Treatment strategies should be individualized based on bipolar disorder subtypes and patient response, with combination therapies often necessary.
  • Further research is needed, particularly double-blind studies for certain agents like clozapine, to fully elucidate their role in bipolar disorder management.